Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression

Clinical and Experimental Immunology

Volumn 123, Issue 1, 2001, Pages 9-14

  Flieger, Dimitri ^a   Hoff, A S ^a   Sauerbruch, T ^a   Schmidt Wolf, I G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cytokines; EpCAM; Flow cytometry; LewisY; Monoclonal antibodies

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CYTOKINE; EDRECOLOMAB; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IRINOTECAN; MITOMYCIN C; MONOCLONAL ANTIBODY; OXALIPLATIN; RALTITREXED;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL ADHESION MOLECULES; CYTOKINES; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HT29 CELLS; HUMANS; INTERFERONS; INTERLEUKINS; LEWIS BLOOD-GROUP SYSTEM; MACROPHAGE COLONY-STIMULATING FACTOR; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; THIOPHENES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0035143524     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01435.x     Document Type: Article

References (54)

1. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes
2. Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity
3. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon
4. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma
5. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies
6. Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12
7. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity
8. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity
9. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells
10. The combination of interleukin-2 and interferon-α effectively augments the antibody dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29
11. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2
12. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines
13. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy
14. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
15. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies
16. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
17. The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues
18. Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12
19. Abnormal blood monocytes in chronic lymphocytic leukemia
20. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells
21. Enhancement of carcinoembryonic antigen expression by interferon
22. In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons
23. Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer
24. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons
25. Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer
26. Expression of transferrin- and interleukin-2-receptors, and HLA-DR in human lung carcinoma
27. Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2
28. Human melanoma cells express a functional interleukin-2 receptor
29. Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells
30. Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression
31. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: Role for endogenous IFN-beta
32. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer
33. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors
34. Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4
35. In vitro upregulation of carcinoembryonic antigen expression by combinations of cytokines
36. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies
37. The fate of antibodies bound to the surface of tumor cells in vitro
38. Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes
39. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells
40. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: Effect of 5-fluorouracil
41. The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2′-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines
42. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells
43. Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells
44. Interferons alpha-2a and beta increase the antitumor activity, detected by MTT assay, of 5-fluorouracil against experimental and clinical human gastrointestinal carcinomas
45. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05
46. Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma
47. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer
48. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
49. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients
50. The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy
51. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2)
52. Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines
53. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
54. Immunoembolization of the liver with IFN-a/IL-2 and intravenous treatment with monoclonal antibody 17-1A in patients suffering from colorectal liver metastasis